<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9D7015D3-F2EE-429B-8EC5-D42600C6391B"><gtr:id>9D7015D3-F2EE-429B-8EC5-D42600C6391B</gtr:id><gtr:firstName>Maryse</gtr:firstName><gtr:surname>Bailly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B8B460BB-2C6E-41DD-B963-764DFE9F5171"><gtr:id>B8B460BB-2C6E-41DD-B963-764DFE9F5171</gtr:id><gtr:firstName>Peng Tee</gtr:firstName><gtr:surname>Khaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A32BD451-FBEB-4F05-BEE2-18D6B4FEAB77"><gtr:id>A32BD451-FBEB-4F05-BEE2-18D6B4FEAB77</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0100195"><gtr:id>000C62E5-3074-400E-886A-CAC4466FF536</gtr:id><gtr:title>Molecular mechanisms underlying fibroblast motility and scar contraction during ocular wound healing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100195</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>187427</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TED patient information day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5C49057C-F184-4189-A5E8-247E4C08E5A0</gtr:id><gtr:impact>This was the first Patient and Public Involvement day for TED and it was well attended (over 100 patients and family). The day received very positive feedback, and achieved its key objective - namely to encourage patient engagement with researchers in identifying priorities and improving trial design. An invaluable insight was gained into patients' needs for a better quality-of-life.

An invaluable insight was gained into patients' needs for a better quality-of-life.
Of 100 attendees, 70 completed questionnaires (35 patients, 9 supporters, 4 exhibitors, 15 healthcare professionals, and 7 'others'). When asked whether the day had provided what they wanted, 48/52 (92%) said &amp;quot;yes&amp;quot;, 3/52 (6%) said &amp;quot;no&amp;quot;. Overall 6/52 (12%) rated it &amp;quot;good&amp;quot;, 28/52 (54%) &amp;quot;very good&amp;quot;, and 18/52 (34%) &amp;quot;excellent&amp;quot;. Thirty-six patients registered to participate in further research and identified &amp;quot;finding the cause for TED&amp;quot;, &amp;quot;improving psychological support&amp;quot;, and &amp;quot;achieving a better cosmetic outcome&amp;quot;, as key priorities for future research. A poor understanding of TED amongst medical professionals was a common complaint.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fight For Sight Project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:fundingRef>1452/1453</gtr:fundingRef><gtr:id>FBA1108A-208D-4B11-9CEC-E405DAE67EA6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fight For Sight Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>5C6A0D74-5421-43C4-B241-94E6CF3508C7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>497792</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Models of Disease Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>655D8308-E1A6-49D4-BEA7-F6ED475E1086</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249406</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AC075513-A564-47AE-A015-EC77D29922E2</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have develop a more physiological model to study tissue contraction using ex-vivo maintained conjunctiva</gtr:description><gtr:id>26FDCBA0-6B65-496D-A1EF-2D63ED0F4882</gtr:id><gtr:impact>the model is now published (in press) and will be available for all to use. We already have developed it further to test novel anti-scarring drugs</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ex-vivo model of conjunctival tissue contraction</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new model to image tissue contraction in vitro live</gtr:description><gtr:id>2D69E7FF-E407-4D62-9B23-D8E98CFCFEA2</gtr:id><gtr:impact>identification of two phases in tissue contraction, improvement in the knowdledge of the basic molecular mechanisms of tissue contraction, development of better models for contraciton and scarring</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>new tissue contraction model</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>development of new imaging techniques to visualise matrix and cells live in 3D, as well as quantitate both the cell dynamic activity and the local tissue contraction</gtr:description><gtr:id>01EFABCC-9C85-48AD-8C3B-DD219C84B41E</gtr:id><gtr:impact>techniques now used by other groups to study scarring</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>new imaging techniques</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>primary ocular fibroblast cell lines with different contraction abilities</gtr:description><gtr:id>316888F9-93A0-48A2-898D-DC329442D797</gtr:id><gtr:impact>better resources to study ocular tissue contraction</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>primary ocular fibroblast cell lines</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF832B7F-1711-4C96-92F3-4BBE108B1BE1"><gtr:id>CF832B7F-1711-4C96-92F3-4BBE108B1BE1</gtr:id><gtr:title>The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b3f6f15e5d4e5acf05d2d732064c30f"><gtr:id>9b3f6f15e5d4e5acf05d2d732064c30f</gtr:id><gtr:otherNames>Martin-Martin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18F8581A-60D6-4A16-9C6B-36BCE99378A9"><gtr:id>18F8581A-60D6-4A16-9C6B-36BCE99378A9</gtr:id><gtr:title>Dynamic protrusive cell behaviour generates force and drives early matrix contraction by fibroblasts.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82637c6814a1149042801517b33edc46"><gtr:id>82637c6814a1149042801517b33edc46</gtr:id><gtr:otherNames>Dahlmann-Noor AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B64A4571-EFBD-4046-BD0C-3A8646CB2625"><gtr:id>B64A4571-EFBD-4046-BD0C-3A8646CB2625</gtr:id><gtr:title>The role of the MRTF-A/SRF pathway in ocular fibrosis.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97b274883a1e43c32b7d3477aca9ca99"><gtr:id>97b274883a1e43c32b7d3477aca9ca99</gtr:id><gtr:otherNames>Yu-Wai-Man C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8029F9D6-9318-4BE5-8E1D-7E3CA41DC2C6"><gtr:id>8029F9D6-9318-4BE5-8E1D-7E3CA41DC2C6</gtr:id><gtr:title>Advancing the treatment of conjunctival scarring: a novel ex vivo model.</gtr:title><gtr:parentPublicationTitle>Archives of ophthalmology (Chicago, Ill. : 1960)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b847abee8ff432e1aa86afb9f5a4dec5"><gtr:id>b847abee8ff432e1aa86afb9f5a4dec5</gtr:id><gtr:otherNames>Tovell VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9950</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100195</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>